Zabalafin Hydrogel (AB-101a)
Atopic Dermatitis
Key Facts
About Alphyn Biologics
Alphyn Biologics is a private, clinical-stage biotech focused on transformative dermatology treatments. The company leverages its proprietary Zabalafin Platform to develop Multi-Target Therapeutics (MTT) that simultaneously address inflammation, infection, and itch in skin diseases. Its lead program, zabalafin hydrogel, has shown positive Phase 2a results in atopic dermatitis and is now in a global Phase 2b trial, with a second program for molluscum contagiosum also in Phase 2. Founded in 2016 and headquartered in Boston, Alphyn aims to become a leader in dermatology by addressing unmet needs for safe, long-term therapies.
View full company profileAbout Alphyn Biologics
Alphyn Biologics is a private, clinical-stage biotech focused on transformative dermatology treatments. The company leverages its proprietary Zabalafin Platform to develop Multi-Target Therapeutics (MTT) that simultaneously address inflammation, infection, and itch in skin diseases. Its lead program, zabalafin hydrogel, has shown positive Phase 2a results in atopic dermatitis and is now in a global Phase 2b trial, with a second program for molluscum contagiosum also in Phase 2. Founded in 2016 and headquartered in Boston, Alphyn aims to become a leader in dermatology by addressing unmet needs for safe, long-term therapies.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |